Virbac has announced the acquisition of Sasaeah from ORIX Corporation for €280 million, boosting its position in Japan's animal health market, particularly in farm animal vaccines.

Target Company Overview

Virbac has entered into a definitive agreement to acquire Sasaeah, an animal health subsidiary of ORIX Corporation, for an enterprise value of approximately €280 million. Sasaeah was formed through the merger of two established animal health entities: Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc. Under ORIX's management, Sasaeah has generated annual revenues of about €75 million, with 50% of its revenue derived from vaccines.

Sasaeah possesses a strong market presence in Japan, focusing on the development, manufacturing, and marketing of a diverse range of veterinary products aimed at both farm animals and companion animals. The acquisition will enhance Virbac's product offerings and solidify its position within the competitive animal health market.

Industry Overview in Japan

The animal health industry in Japan is one of the most advanced in Asia, characterized by a growing demand for innovative veterinary products due to an increase in pet ownership and con